Holen Sie sich die Stockscreener-App
2.67
4.30%
0.11
Handel nachbörslich:
2.69
0.02
+0.75%
Schlusskurs vom Vortag:
$2.56
Offen:
$2.65
24-Stunden-Volumen:
1.31M
Relative Volume:
0.91
Marktkapitalisierung:
$190.03M
Einnahmen:
$20.76M
Nettoeinkommen (Verlust:
$-132.49M
KGV:
-1.00
EPS:
-2.67
Netto-Cashflow:
$-108.55M
1W Leistung:
+4.71%
1M Leistung:
+27.14%
6M Leistung:
+12.18%
1J Leistung:
-54.51%
1-Tages-Spanne:
$2.58
$2.695
1-Wochen-Bereich:
$2.33
$2.72
52-Wochen-Spanne:
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Vergleichen Sie CCCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.67 | 178.64M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
C4 Therapeutics to Present Updated Data on Cemsidomide for Multiple Myeloma at IMS Annual Meeting 2025 - Quiver Quantitative
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting - The Manila Times
C4 Therapeutics to Present Data from the Phase 1 Trial of - GlobeNewswire
Novel Multiple Myeloma Drug Trial Results: C4 Therapeutics' Cemsidomide Shows Promise in Phase 1 Study - Stock Titan
Can C4 Therapeutics Inc. recover in the next quarterIPO Watch & Real-Time Chart Pattern Alerts - Newser
How moving averages guide C4 Therapeutics Inc. trading2025 Winners & Losers & High Accuracy Investment Entry Signals - Newser
Historical volatility pattern of C4 Therapeutics Inc. visualized2025 Technical Patterns & Entry and Exit Point Strategies - Newser
Building trade automation scripts for C4 Therapeutics Inc.Day Trade & Free Risk Controlled Daily Trade Plans - Newser
Detecting support and resistance levels for C4 Therapeutics Inc.2025 Analyst Calls & AI Enhanced Trade Execution Alerts - Newser
Best data tools to analyze C4 Therapeutics Inc. stockJuly 2025 Spike Watch & Weekly Market Pulse Alerts - Newser
Why is C4 Therapeutics Inc. stock going downJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - khodrobank.com
What is C4 Therapeutics Inc.’s book value per shareLong Setup & Daily Chart Pattern Signals - khodrobank.com
Protara Therapeutics’ Equity Inducement Grants: A Strategic Catalyst for Talent Retention and Long-Term Value Creation - AInvest
Entrada Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Protara Therapeutics, Inc. reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Akebia Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Chart overlay techniques for tracking C4 Therapeutics Inc.GDP Growth & Weekly Market Pulse Alerts - Newser
Can C4 Therapeutics Inc. weather a recessionPortfolio Growth Summary & Weekly Market Pulse Updates - khodrobank.com
Identifying reversal signals in C4 Therapeutics Inc.Chart Signals & Safe Capital Investment Plans - Newser
Is C4 Therapeutics Inc. stock overvalued or fairly priced2025 Market Outlook & AI Driven Price Predictions - khodrobank.com
Quarterly Earnings: What are the analyst revisions for NOVAIs C4 Therapeutics Inc. stock a good investment in YEAR - khodrobank.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Can momentum traders help lift C4 Therapeutics Inc.Watch List & Fast Moving Stock Trade Plans - Newser
Can C4 Therapeutics Inc. sustain its profitabilityPortfolio Profit Report & High Accuracy Trade Alerts - khodrobank.com
Is C4 Therapeutics Inc. meeting your algorithmic filter criteriaRate Cut & Community Trade Idea Sharing - Newser
C4 Therapeutics Inc. Crosses 200 Day MA — Signal or Noise getLinesFromResByArray error: size == 0 - kangso.co.kr
Is It Too Early to Call Recovery in C4 Therapeutics Inc. getLinesFromResByArray error: size == 0 - kangso.co.kr
Is C4 Therapeutics Inc. stock suitable for long term investing2025 Macro Impact & Community Consensus Stock Picks - خودرو بانک
Identifying reversal signals in C4 Therapeutics IncJuly 2025 News Drivers & Verified Swing Trading Watchlist - Newser
Market reaction to C4 Therapeutics Inc.’s recent newsRate Cut & AI Enhanced Trading Signals - Newser
Real time breakdown of C4 Therapeutics Inc. stock performance2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Is it time to cut losses on C4 Therapeutics Inc.Weekly Profit Report & Community Trade Idea Sharing - Newser
Is C4 Therapeutics Inc. forming a reversal patternWall Street Watch & Safe Swing Trade Setups - Newser
Does C4 Therapeutics Inc. show high probability of rebound2025 Volatility Report & AI Powered Buy/Sell Recommendations - Newser
Backtesting results for C4 Therapeutics Inc. trading strategiesEarnings Trend Report & Technical Buy Zone Confirmation - Newser
Using Bollinger Bands to evaluate C4 Therapeutics Inc.July 2025 Short Interest & Accurate Buy Signal Alerts - Newser
C4 Therapeutics Inc. Recovers — But Is It Sustainable getLinesFromResByArray error: size == 0 - 클래시안
Published on: 2025-08-31 09:26:19 - beatles.ru
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
C 4 Therapeutics Inc-Aktie (CCCC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):